Loading clinical trials...
Loading clinical trials...
A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients
Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.
Age
50 - 80 years
Sex
ALL
Healthy Volunteers
No
Kansai region
Kansai, Japan
Kanto region,
Kanto, Japan
Kyushu region
Kyushu, Japan
Tokai region
Toakai, Japan
Tohoku region
Tōhoku, Japan
Start Date
June 1, 2012
Primary Completion Date
March 1, 2014
Completion Date
June 1, 2014
Last Updated
September 19, 2014
28
ACTUAL participants
Gantenerumab
DRUG
Gantenerumab
DRUG
Gantenerumab
DRUG
Placebo
DRUG
Lead Sponsor
Chugai Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07033494